Interprotein, Takeda deal

The companies partnered to design and develop protein-protein interaction inhibitors for undisclosed indications. Interprotein will use its Engine for New Drug Design (INTENDD) technology to design small molecule protein-protein interaction inhibitors against an undisclosed target from Takeda, which will conduct drug discovery research based on the design from Interprotein. The partners declined to disclose details. ...